Home > About us > History
Itami plaster(For export) approved
A research collaboration agreement with Takeda Pharmaceutical Company Limited
Suture Neosorb plus(For export) approved
Samyang Tulobuterol patch(For export) approved
Iran GMP certification for pharmaceuticals received
Docetaxel-PNP receives IND approval
Nanoxel injection(docetaxel) approved
Nicostop Gum approved
Genexol-PM approved in India
Genexol-PM receives IND approval (phase II on ovarian cancer)
Genexol-PM approved in Vietnam
Genexol-PM approved in Philippine
Anti-adhesion Barrier Poligogel receives IND approval
Genexol approved in Serbia
Genexol-PM receives IND approval (phase I on ovarian cancer)
Docetaxel-PM receives IND approval
Capsaicin plaster IND approval
Loratadine FDT approved
Suture Neosorb approved
Hernia mesh Proflex approved
Genexol-PM wins Korea New Drug Award
GENEXOL-PM™ (next generation anti-cancer agent using Paclitaxel, injection)
marketed in Korea
Daedeok pharmaceutical plant extended
Genexol-PM wins Health industry & technology award
Medical management information system built
Nicostop troche approved
Nexatin injection(oxaliplatin) approved
"Business Agreement" reached with Akina, Inc. of the U.S. on Cetirizine FDT
"R&D Agreement" reached with Hyundai Pharmaceutical of Korea on Cetirizine
Hydrochloride FDT
Phase II clinical trials of Genexol PM on breast cancer II initiated at Asan Medical Center, etc.
Suture Monosorb-Pro approved
Genexol Injection certified as effective in gastric cancer treatment
"R&D Agreement" reached with Akina, Inc. of the U.S.
Phase II clinical trials of Genexol PM on non-small cell lung cancer initiated
at Seoul National University Hospital, etc.
Phase II clinical trials of Genexol PM on breast cancer I initiated
at Seoul National University Hospital, etc.
Genexol Injection certified as effective in ovarian cancer treatment
"R&D Agreement" reached with Lavipharm of Greece and technical transfer of
Nicostop completed
Genexol Injection certified as effective in lung cancer treatment
Pharmaceutical research corporation established in Utah Samyang Research Corporation
(SRC)
Genexol-PM receives U.S. IND approval
100 mg Genexol-PM Injection approved
"Business Agreement" reached with Akina, Inc. of the U.S.
30 mg Genexol-PM Injection approved
Genexol Injection certified as effective in breast cancer treatment
"R&D Agreement" reached with Transform Pharmaceuticals, Inc. of the U.S.
"Business Agreement" reached with Transform Pharmaceuticals, Inc. of the U.S.
Surgisorb and BioMesh acquire CE mark
Three R&D Agreementsreached with MacroMed, Inc. of the U.S. on hGH, pGH,
Tramadol, and G-CSF
Medical devices acquire ISO 9001 & EN 46001 certification
BioMesh approved
KGMP certification for medical device received
Genexol Injection approved and released (Jun 1, 2001)
Reumastop Plaster approved
Surgisorb, an absorbable suture product, approved and released (Dec 1, 1998)
Trisorb wins Jang Young Shil Award
Nicostop patches approved
KGMP certification for pharmaceuticals received
"Business Agreement" reached with AmCyte, Inc. of the U.S.
"Business Agreement" reached with VivoRx Pharmaceutical, Inc. of the U.S.
"R&D Agreement" reached with MacroMed, Inc. of the U.S. and Gene Delivery System
developed
"R&D Agreement" reached with TheraTech, Inc. of the U.S. on Combitran-MTX
"R&D Agreement" reached with TheraTech, Inc. of the U.S. on Estran-MTX
Medical suture products win patented technology award
"R&D Agreement" reached with TheraTech, Inc. of the U.S. on Androderm-LRS
and Angiderm-MTX patches
"Business Agreement" reached with MacroMed, Inc. of the U.S.
Medical suture products granted the Korea Good Technology mark
Pharmaceutical Research Center established
Copyright 2011 by Samyang Biopharmaceuticals Corporation. All rights reserved.